Abstract Cationic defence peptides show high therapeutic potential as antimicrobial and anticancer agents. Some of these peptides carry a C-terminal amide moiety which has been shown to be required for antimicrobial activity. However, whether this is a general requirement or whether C-terminal amidation is required for the anticancer activity of defence peptides is unclear. In response, this study analyses the toxicity of a series of C-terminally amidated defence peptides and their non-amidated isoforms to normal fibroblast cells, a variety of tumour cells and bacterial cells. The toxicities of these peptides to microbial and cancer cells were generally \200 lM. Peptides were either unaffected by C-terminal amidation or showed up to 10-fold decreases or increases in efficacy. However, these peptides all showed toxicity to normal fibroblast cells with levels (generally \150 lM) that were comparable to those of their antimicrobial and anticancer activities. In contrast to previous claims which have been based on analysis of single amidation events, the results of this study clearly show that the C-terminal amidation of defence peptides has a variable effect on their antimicrobial and anticancer efficacy and no clear effect on their selectivity for these cell types.
Introduction
The increasing occurrences of resistance to antimicrobial and anticancer agents are two major challenges facing medical research and defence peptides are attractive propositions for the solution of both problems. These peptides have a major advantage over conventional antibiotics and anticancer drugs in that currently microbes and tumours show little evidence of resistance to their toxic action, which involves relatively non-specific interactions with target cell membranes [1] . Nonetheless, a full understanding of factors influencing the antimicrobial and anticancer activities of defence peptides is still lacking, which hampers development of their full therapeutic potential [1, 2] .
It is generally accepted that the ability of defence peptides to kill microbes and cancer cells primarily depends upon their positive charge, which enables electrostatic binding to anionic components of the target cell membrane, and their structural amphiphilicity, which facilitates bilayer penetration and disruption resulting in cell death. It is also well established that the positive charge carried by defence peptides mainly derives from the presence of lysine and arginine residues within their sequences [3] . However, the positive charge of some defence peptides also includes a contribution from a C-terminal amide moiety, and there is evidence to suggest that the presence of this amide group enhances the antimicrobial activity. Examples where this has been demonstrated include: the a-helical antimicrobial amphibian peptide, peptidyl-glycylleucine-carboxyamide (PGLa) [4] , the b-sheet human a-defensin, human neutrophil alpha-defensin 2 (HNP2) [5] and the turn/turn porcine peptide, tritrpticin [6] .
Over the last decade, it has become clear that the antimicrobial and anticancer actions of defence peptides show similarities. In particular, the ability of defence peptides to kill cancer cells also involves electrostatic interactions between these cationic peptides and anionic components of the cancer cell membrane [7] . Based on this observation, it has recently been suggested that C-terminal amidification may enhance the anticancer activity of defence peptides [8] although little research into this possibility appears to have been undertaken. Taking this into consideration, this study was designed to investigate these suggestions by assembling a database of C-terminally amidated peptides along with their non-amidated isoforms and analysing their toxicity to a variety of eukaryotic and prokaryotic cells.
Materials and methods

Database assembly and cell line toxicity analysis
The sequences of a series of C-terminally amidated (AM) peptides along with their non-C-terminally amidated (AC) isoforms (Table 1) were extracted from a database of naturally occurring and synthetic defence peptides [9] . Toxicity data for these AC/AM isoforms against WI38, a normal fibroblast cell line of the lung diploid cells, and a variety of tumour cell lines were extracted as the half lethal dose (LD 50 ) [9] . These tumour cell lines included MCF7-a breast adenocarcinoma tumour cell line, SW480-a colon adenocarcinoma tumour cell line, BMKC-a cloned melanoma cell line, H1299-a lung large cell carcinoma tumour cell line, HeLaS3-a cervical epithelial carcinoma cell line and PC3-a prostate adenocarcinoma tumour cell line. Also extracted was toxicity data for these AC/AM isoforms (Table 1) against Escherichia coli (Accession number ATCC 25922), Pseudomonas aeruginosa (Accession number ATCC 27853) and Staphylococcus aureus (Accession number ATCC 25923) as the minimum inhibitory concentration (MIC) [9] . These various toxicity data were then graphically represented and compared to detect putative relationships between the toxicity levels of these peptides and their possession of C-terminal amidation. A t-test was also applied to the data to investigate whether there was a significant difference between the AM and AC isoforms active against the bacterial cell lines.
Extended hydrophobic moment and hydropathy analysis
For each peptide, the mean hydrophobic moment, hl H i, and the mean hydrophobicity, hHi, were calculated according to Eisenberg et al. [10] and analysed according to the extended hydrophobic moment plot diagram of Harris et al. [11] . AM/AC peptide isoforms were analysed for hydrophobicity gradients using the program Winpep v3.0 [12] , which represented sequences as conventional hydropathy plots using the hydrophobicity scale of Eisenberg et al. [10] and an 11-residue sliding window. For each sequence analysed, hydrophobicity gradients were then determined by visual inspection and were reported as the change in hydrophobicity per residue of peptide over the length of the gradient along with the direction of the gradient. Toxicity data were used to calculate the toxicity ratio of N-C/N-N isoforms for each individual cell line as an indicator of the effect of amidation on toxicity. The ratios Table 1 The sequences of C-terminally amidated peptides (AM) and their non-C-terminally amidated (AC) isoforms, which were extracted from the database of Owen [9] Name Sequence were then plotted against the hydrophobicity gradient per residue subjected to linear regression analysis.
Results and discussion
Factors influencing the anticancer activities of defence peptides are poorly understood. To date, most studies on defence peptides have focussed on their antimicrobial activity. These studies showed that C-terminal amidation is the most common post-translational modification of defence peptides, which clearly suggested biological relevance, and led a number of recent studies to show that possession of this C-terminal moiety enhanced the antimicrobial activity of these peptides [4, 5, 13] . In order to gain further insight into these factors, this study investigates the possibility that the C-terminal amide group carried by some defence peptides may enhance their antimicrobial and anticancer action. In order to test the generality of this amidation effect, this study compared the toxicity of a series of C-terminally amidated (AM) peptides to prokaryotic cells with that of their non-C-terminally amidated (AC) isoforms (Table 1) . In general, the AM and AC isoforms in Table 1 are strongly antibacterial with levels of toxicity that lie in the range of 5-150 lM (Fig. 1) . These data clearly show that the toxicity of defence peptides to microbial cells can be unaffected, increased or decreased by the presence of a C-terminal amide moiety, indicating that this structural modification has a variable effect on their antimicrobial efficacy. The application of a t-test revealed that there were no significant differences between the AM and AC isoforms active against E. coli (T = -0.315; P = 0.768), P. aeruginosa (T = -2.44; P = 0.071) and S. aureus (T = -1.633; P = 0.178). Whilst there is no consistent effect of amidation on antibacterial activity, the addition of the amide group could in some cases have a significant effect on activity. For example, the potency of Flak 06 and FLAK 26 AM isoforms on S. aureus was up to eightfold higher than their AC counterparts.
Examination of Fig. 2 shows that each of the AC and AM isoforms studied was strongly toxic to the normal fibroblast cell line, W138, with toxicity levels that were in the range of 5-150 lM and comparable to those of their antimicrobial activity (Fig. 1) . Based on similarities between the antimicrobial and anticancer actions of defence peptides, it has recently been suggested that C-terminal amidification may enhance activity of defence peptides against cancer cells [8] . In general, the AM and AC isoforms in Table 1 show strong activity against cancer cells with levels that are generally in (Fig. 2) and are therefore comparable to those of their antimicrobial potency (Fig. 1) . Again, whilst amidation had an effect on activity in some cases, as with the antibacterial activity, the paired t-test revealed that there were no significant differences between the AM and AC isoforms for SW480 (T = 1.881; P = 0.119), BMKC (T = 0.258; P = 0.806), H1299 (T = 1.782; P = 0.135), HeLaS3 (T = 0.550; P = 0.606) and PC3 (T = 0.025; P = 0.981) cell lines.
Furthermore, comparison of the bacterial and eukaryotic selectivity for AM peptides could distinguish no statistical difference. A similar result was seen for AC isoforms, implying that these peptides do not differentiate between cell types. These data clearly show that C-terminal amidation of the peptides studied does not affect their selectivity for microbial cells over eukaryotic cells. Evidence to support this conclusion, was recently shown that the C-terminal amidation of some aureins, which are amphibian defence peptides, had no apparent effect on the ability of these peptides to discriminate between prokaryotic and eukaryotic cells [14] .
A number of studies have shown that increasing the positive charge of peptides can enhance their antimicrobial activity [4] . Despite amidation having increased the net positive charge of peptides analysed in this study (Table 1) , this structural modification had a variable effect on their antimicrobial efficacy. Therefore, in order to gain knowledge on the structure-antimicrobial activity relationship of the peptides, extended hydrophobic moment plot methodology was used to characterise the overall molecular architecture on the membrane interactive potential of the peptides. Here, extended hydrophobic moment plot analysis of AM/AC isoforms (Fig. 3) predicted these peptides to form surface active a-helices. However, Hectate AC/AM (Fig. 4a) , SB-37 AC/AM (Fig. 4b) , Shiva 10 AC/AM (Fig. 4c) , FLAK 06 AC/AM (Fig. 4d) FLAK 26 AC/AM (Fig. 4e) and Hectate ACV/ AVM (Fig. 4i) , were found to possess hydrophobicity gradients (Fig. 4) , which is characteristic structural feature of tilted peptides, providing an asymmetric distribution of hydrophobicity along the a-helical long axis, which facilitates shallow bilayer penetration and a range of membrane disruptive effects [11] . In contrast, it can also be seen from Fig. 4 that Shiva 10(1-18) AC/AM (Fig. 4f) possessed a negligible hydrophobicity gradient whilst CA(1-7)Shiva10(1-16) AC/AM (Fig. 4g) and Modelin-5 COOH/ NH 2 (Fig. 4h) exhibited irregular trends in hydrophobicity with no significant gradient discernable. It has previously been suggested that the efficacy of some ACPs may be related to the possession of hydrophobicity gradients along their a-helical long axis [7] . However, examination of Fig. 4 shows that whilst these hydrophobicity gradients vary in magnitude and direction, comparison of Fig. 4 with toxicity data (Figs. 1 and 2) showed no apparent relationship between these gradient properties and either the cell line toxicity of the parent peptides or the range of the cell lines they target. However, when the effect of amidation on toxicity was considered as a function of hydrophobicity gradient (Fig. 5) , weak negative correlations were observed. Across the cells lines tested, amidation appears to have a greater tendency to decrease toxicity when larger hydrophobicity gradients are present. In contrast when there is limited or no hydrophobicity gradient amidation appears more likely to increase efficacy. In the former case the gradient may be associated with penetration of the bilayer core which could be disrupted by amidation therefore decreasing efficacy. In the case of a low gradient the peptide would be predicated to act by use of a carpet mechanism with binding driven surface activity at the membrane interface. In this latter case binding could be enhanced may the effect of amidation of the physicochemical properties such as charge distribution, thereby increasing efficacy.
In summary, in contrast to previously published research on single peptide amidation, this analysis shows that C-terminal amidification has no reproducible effect on either the selectivity or the efficacy of defence peptides, which needs to be considered in the context of the peptide structure and its target cell. The presence of this structural moiety had a variable effect on the toxicity of defence peptides to both microbial and cancer cells. It does appear that the presence and magnitude of a hydrophocity gradient along the helical long axis can modify the effect of amidation on toxicity. In the case of large gradients there appears to be greater likelihood of amidation decreasing efficacy in contrast to increase in efficacy seen in the presence of limited gradient. This may reflect differences in mode of action with those peptides possessing gradient adopting tilt structures with penetration into the bilayer core and those without acting on the outer leaflet via carpet type mechanisms.
